Please Wait
Applying Filters...
menu
    • menu
    CDMO Activity Tracker: Lupin’s CDMO commissions oncology block in India; Cambrex, Axplora, Hovione expand operations

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    Lafutidine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,304Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    30/12/2025 ACE Japan Co Ltd
    Japan
    		 Ace Japan Co., Ltd. 302MF10113 Japanese Pharmacopoeia Lafutidine 2020-09-24 2020-09-24 5850-1 Higashineko, Higashine City, Yamagata Prefecture
    30/12/2025 ACE Japan Co Ltd
    Japan
    		 Ace Japan Co., Ltd. 304MF10047 Japanese Pharmacopoeia Lafutidine 2022-03-02 2022-03-02 5850-1 Higashineko, Higashine City, Yamagata Prefecture
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.